Anthera Pharmaceuticals Inc., a San Mateo, Calif.-based developer of anti-inflammatory drugs, has set its proposed IPO terms to around 4.61 million common shares being offered at between $13 and $15 per share. The company plans to trade on the Nasdaq under ticker symbol ANTH, with Deutsche Bank Securities serving as lead underwriter.
Anthera has raised around $75 million in VC funding, from firms like VantagePoint Venture Partners (32.97% pre-IPO stake), Sofinnova Ventures (21.24%), Caxton Advantage Life Sciences Fund (6.09%), HBM BioCapital (6.07%), Pappas Ventures (5.55%) and Mitsubishi International Corp. www.anthera.com
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.